Review





Similar Products

genechip human genome u133 plus 2.0 oligonucleotide arrays  (Thermo Fisher)
90
Thermo Fisher genechip human genome u133 plus 2.0 oligonucleotide arrays
Genechip Human Genome U133 Plus 2.0 Oligonucleotide Arrays, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genechip+human+genome+u133+plus+2%2E0+arrays/seebluetm+plus2+pre+stained+protein+standard/pmc10646561__EMBJ___42___e114032___s001-276-20-22
Average 90 stars, based on 1 article reviews
genechip human genome u133 plus 2.0 oligonucleotide arrays - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
genechip tm human genome u133 plus 2.0 array  (Thermo Fisher)
90
Thermo Fisher genechip tm human genome u133 plus 2.0 array
GCS is involved in modulating gene expression of ovarian cancer cells in response to dactinomycin treatments. Cells of NCI/ADR-RES/Mock (Mock), NCI/ADR-RES/GCS (GCS), and NCI/ADR-RES/asGCS (asGCS) ovarian cancer cell lines were treated with 25 nM dactinomycin (DAC) in 5% FBS for 24 h. The mRNA levels of genes were analyzed by using Affymetrix GeneChip ® Human Genome <t>U133</t> Plus 2.0 and Transcriptome Analysis Console (TAC 4.0). ( A ), differential gene-expression profiles of NCI/ADR-RES cells in response to DAC treatments. Differential expression of probed genes was identified as those having transcript levels 2-fold higher (up-regulated) or 2-fold lower (down-regulated) for the cells with treatment than those of comparator cells. ( B ), Overlaps of gene profiles of NCI/ADR-RES cells with treatments. GCS-responsive genes (overlap AB areas) are identified as those exhibiting their expression levels up-regulated in ADR-RES/GCS cells versus down-regulated in ADR/RES/asGCS cells (vice versa) treated with vehicle (left) or DAC (right), respectively.
Genechip Tm Human Genome U133 Plus 2.0 Array, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genechip+human+genome+u133+plus+2%2E0+arrays/seebluetm+plus2+pre+stained+protein+standard/pmc12155275-247-1-9
Average 90 stars, based on 1 article reviews
genechip tm human genome u133 plus 2.0 array - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
genechip human genome u133 plus 2.0 array  (Fisher Scientific)
90
Fisher Scientific genechip human genome u133 plus 2.0 array
GCS is involved in modulating gene expression of ovarian cancer cells in response to dactinomycin treatments. Cells of NCI/ADR-RES/Mock (Mock), NCI/ADR-RES/GCS (GCS), and NCI/ADR-RES/asGCS (asGCS) ovarian cancer cell lines were treated with 25 nM dactinomycin (DAC) in 5% FBS for 24 h. The mRNA levels of genes were analyzed by using Affymetrix GeneChip ® Human Genome <t>U133</t> Plus 2.0 and Transcriptome Analysis Console (TAC 4.0). ( A ), differential gene-expression profiles of NCI/ADR-RES cells in response to DAC treatments. Differential expression of probed genes was identified as those having transcript levels 2-fold higher (up-regulated) or 2-fold lower (down-regulated) for the cells with treatment than those of comparator cells. ( B ), Overlaps of gene profiles of NCI/ADR-RES cells with treatments. GCS-responsive genes (overlap AB areas) are identified as those exhibiting their expression levels up-regulated in ADR-RES/GCS cells versus down-regulated in ADR/RES/asGCS cells (vice versa) treated with vehicle (left) or DAC (right), respectively.
Genechip Human Genome U133 Plus 2.0 Array, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genechip+human+genome+u133+plus+2%2E0+arrays/clariom+s+mouse+arrays/pmc12082741-30-10-23
Average 90 stars, based on 1 article reviews
genechip human genome u133 plus 2.0 array - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
genechip human genome u133 plus 2.0 arrays  (Thermo Fisher)
90
Thermo Fisher genechip human genome u133 plus 2.0 arrays
GCS is involved in modulating gene expression of ovarian cancer cells in response to dactinomycin treatments. Cells of NCI/ADR-RES/Mock (Mock), NCI/ADR-RES/GCS (GCS), and NCI/ADR-RES/asGCS (asGCS) ovarian cancer cell lines were treated with 25 nM dactinomycin (DAC) in 5% FBS for 24 h. The mRNA levels of genes were analyzed by using Affymetrix GeneChip ® Human Genome <t>U133</t> Plus 2.0 and Transcriptome Analysis Console (TAC 4.0). ( A ), differential gene-expression profiles of NCI/ADR-RES cells in response to DAC treatments. Differential expression of probed genes was identified as those having transcript levels 2-fold higher (up-regulated) or 2-fold lower (down-regulated) for the cells with treatment than those of comparator cells. ( B ), Overlaps of gene profiles of NCI/ADR-RES cells with treatments. GCS-responsive genes (overlap AB areas) are identified as those exhibiting their expression levels up-regulated in ADR-RES/GCS cells versus down-regulated in ADR/RES/asGCS cells (vice versa) treated with vehicle (left) or DAC (right), respectively.
Genechip Human Genome U133 Plus 2.0 Arrays, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genechip+human+genome+u133+plus+2%2E0+arrays/seebluetm+plus2+pre+stained+protein+standard/pm39920332-108-6-13
Average 90 stars, based on 1 article reviews
genechip human genome u133 plus 2.0 arrays - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
genechip™ human genome u133 plus 2.0 array  (Thermo Fisher)
90
Thermo Fisher genechip™ human genome u133 plus 2.0 array
GCS is involved in modulating gene expression of ovarian cancer cells in response to dactinomycin treatments. Cells of NCI/ADR-RES/Mock (Mock), NCI/ADR-RES/GCS (GCS), and NCI/ADR-RES/asGCS (asGCS) ovarian cancer cell lines were treated with 25 nM dactinomycin (DAC) in 5% FBS for 24 h. The mRNA levels of genes were analyzed by using Affymetrix GeneChip ® Human Genome <t>U133</t> Plus 2.0 and Transcriptome Analysis Console (TAC 4.0). ( A ), differential gene-expression profiles of NCI/ADR-RES cells in response to DAC treatments. Differential expression of probed genes was identified as those having transcript levels 2-fold higher (up-regulated) or 2-fold lower (down-regulated) for the cells with treatment than those of comparator cells. ( B ), Overlaps of gene profiles of NCI/ADR-RES cells with treatments. GCS-responsive genes (overlap AB areas) are identified as those exhibiting their expression levels up-regulated in ADR-RES/GCS cells versus down-regulated in ADR/RES/asGCS cells (vice versa) treated with vehicle (left) or DAC (right), respectively.
Genechip™ Human Genome U133 Plus 2.0 Array, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genechip+human+genome+u133+plus+2%2E0+arrays/bio_rxiv__2025__01__12__632620-188-8-7
Average 90 stars, based on 1 article reviews
genechip™ human genome u133 plus 2.0 array - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
genechip® human genome u133 plus 2.0 arrays  (Thermo Fisher)
90
Thermo Fisher genechip® human genome u133 plus 2.0 arrays
GCS is involved in modulating gene expression of ovarian cancer cells in response to dactinomycin treatments. Cells of NCI/ADR-RES/Mock (Mock), NCI/ADR-RES/GCS (GCS), and NCI/ADR-RES/asGCS (asGCS) ovarian cancer cell lines were treated with 25 nM dactinomycin (DAC) in 5% FBS for 24 h. The mRNA levels of genes were analyzed by using Affymetrix GeneChip ® Human Genome <t>U133</t> Plus 2.0 and Transcriptome Analysis Console (TAC 4.0). ( A ), differential gene-expression profiles of NCI/ADR-RES cells in response to DAC treatments. Differential expression of probed genes was identified as those having transcript levels 2-fold higher (up-regulated) or 2-fold lower (down-regulated) for the cells with treatment than those of comparator cells. ( B ), Overlaps of gene profiles of NCI/ADR-RES cells with treatments. GCS-responsive genes (overlap AB areas) are identified as those exhibiting their expression levels up-regulated in ADR-RES/GCS cells versus down-regulated in ADR/RES/asGCS cells (vice versa) treated with vehicle (left) or DAC (right), respectively.
Genechip® Human Genome U133 Plus 2.0 Arrays, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genechip+human+genome+u133+plus+2%2E0+arrays/pmc11739359-84-6-13
Average 90 stars, based on 1 article reviews
genechip® human genome u133 plus 2.0 arrays - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
genechip human genome u133 plus 2.0 array  (Thermo Fisher)
90
Thermo Fisher genechip human genome u133 plus 2.0 array
Statistics of the DEGs for selected intestinal disorders and colon cancer.
Genechip Human Genome U133 Plus 2.0 Array, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genechip+human+genome+u133+plus+2%2E0+arrays/pmc11673540-8-8-7
Average 90 stars, based on 1 article reviews
genechip human genome u133 plus 2.0 array - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


GCS is involved in modulating gene expression of ovarian cancer cells in response to dactinomycin treatments. Cells of NCI/ADR-RES/Mock (Mock), NCI/ADR-RES/GCS (GCS), and NCI/ADR-RES/asGCS (asGCS) ovarian cancer cell lines were treated with 25 nM dactinomycin (DAC) in 5% FBS for 24 h. The mRNA levels of genes were analyzed by using Affymetrix GeneChip ® Human Genome U133 Plus 2.0 and Transcriptome Analysis Console (TAC 4.0). ( A ), differential gene-expression profiles of NCI/ADR-RES cells in response to DAC treatments. Differential expression of probed genes was identified as those having transcript levels 2-fold higher (up-regulated) or 2-fold lower (down-regulated) for the cells with treatment than those of comparator cells. ( B ), Overlaps of gene profiles of NCI/ADR-RES cells with treatments. GCS-responsive genes (overlap AB areas) are identified as those exhibiting their expression levels up-regulated in ADR-RES/GCS cells versus down-regulated in ADR/RES/asGCS cells (vice versa) treated with vehicle (left) or DAC (right), respectively.

Journal: International Journal of Molecular Sciences

Article Title: Glucosylceramide Synthase, a Key Enzyme in Sphingolipid Metabolism, Regulates Expression of Genes Accounting for Cancer Drug Resistance

doi: 10.3390/ijms26115112

Figure Lengend Snippet: GCS is involved in modulating gene expression of ovarian cancer cells in response to dactinomycin treatments. Cells of NCI/ADR-RES/Mock (Mock), NCI/ADR-RES/GCS (GCS), and NCI/ADR-RES/asGCS (asGCS) ovarian cancer cell lines were treated with 25 nM dactinomycin (DAC) in 5% FBS for 24 h. The mRNA levels of genes were analyzed by using Affymetrix GeneChip ® Human Genome U133 Plus 2.0 and Transcriptome Analysis Console (TAC 4.0). ( A ), differential gene-expression profiles of NCI/ADR-RES cells in response to DAC treatments. Differential expression of probed genes was identified as those having transcript levels 2-fold higher (up-regulated) or 2-fold lower (down-regulated) for the cells with treatment than those of comparator cells. ( B ), Overlaps of gene profiles of NCI/ADR-RES cells with treatments. GCS-responsive genes (overlap AB areas) are identified as those exhibiting their expression levels up-regulated in ADR-RES/GCS cells versus down-regulated in ADR/RES/asGCS cells (vice versa) treated with vehicle (left) or DAC (right), respectively.

Article Snippet: The GeneChip TM Human Genome U133 Plus 2.0 Array (Affymetrix; catalog 900466) was purchased from Thermo Fisher Scientific (Waltham, MA, USA).

Techniques: Gene Expression, Quantitative Proteomics, Expressing

Statistics of the DEGs for selected intestinal disorders and colon cancer.

Journal: Biomedicines

Article Title: Integrative Multi-Omics Analysis Reveals Critical Molecular Networks Linking Intestinal-System Diseases to Colorectal Cancer Progression

doi: 10.3390/biomedicines12122656

Figure Lengend Snippet: Statistics of the DEGs for selected intestinal disorders and colon cancer.

Article Snippet: UC , GSE9686 , biopsy samples , Affymetrix GeneChip Human Genome U133 Plus 2.0 Array , USA , 5 , 8 , 2013 , 751 , 1262.

Techniques: Control, Expressing, Next-Generation Sequencing